Currently, there are 113.63M common shares owned by the public and among those 85.23M shares have been available to trade.
The company’s stock has a 5-day price change of -26.52% and -13.67% over the past three months. DYN shares are trading -53.90% year to date (YTD), with the 12-month market performance down to -67.76% lower. It has a 12-month low price of $6.36 and touched a high of $47.45 over the same period. DYN has an average intraday trading volume of 2.59 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -16.69%, -3.77%, and -47.34% respectively.
Institutional ownership of Dyne Therapeutics Inc (NASDAQ: DYN) shares accounts for 83.74% of the company’s 113.63M shares outstanding.
It has a market capitalization of $1.23B and a beta (3y monthly) value of 1.17. The earnings-per-share (ttm) stands at -$3.59. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.30% over the week and 6.45% over the month.
Analysts forecast that Dyne Therapeutics Inc (DYN) will achieve an EPS of -0.94 for the current quarter, -0.94 for the next quarter and -3.76 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -1.14 while analysts give the company a high EPS estimate of -1.14. Comparatively, EPS for the current quarter was -0.7 a year ago. Earnings per share for the fiscal year are expected to decrease by -16.19%, and 3.23% over the next financial year. EPS should grow at an annualized rate of 0.35% over the next five years, compared to -59.45% over the past 5-year period.
Looking at the support for the DYN, a number of firms have released research notes about the stock. Raymond James stated their Outperform rating for the stock in a research note on June 11, 2025, with the firm’s price target at $37. Oppenheimer coverage for the Dyne Therapeutics Inc (DYN) stock in a research note released on June 02, 2025 offered a Outperform rating with a price target of $34. Evercore ISI was of a view on May 29, 2025 that the stock is Outperform, while BMO Capital Markets gave the stock Outperform rating on March 12, 2025, issuing a price target of $50. Scotiabank on their part issued Sector Outperform rating on March 07, 2025.
